Literature DB >> 15134353

Patient selection for prostate brachytherapy: more myth than fact.

Gregory S Merrick1, Kent E Wallner, Wayne M Butler.   

Abstract

Prostate brachytherapy efficacy and morbidity are primarily dependent on implant quality and patient management. While most alleged contraindications to brachytherapy have been propagated based on physician bias rather than clinical data, a number of evidence-based factors contributing to radiation-related morbidity have accumulated. Refinements in patient selection may result in further improvements in biochemical and quality-of-life outcomes. Herein, we have summarized evidence-based vs unsubstantiated patient selection factors that affect outcome.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15134353

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  3 in total

Review 1.  The efficacy of conventional external beam, three-dimensional conformal, intensity-modulated, particle beam radiation, and brachytherapy for localized prostate cancer.

Authors:  Tony Y Eng; Join Y Luh; Charles R Thomas
Journal:  Curr Urol Rep       Date:  2005-05       Impact factor: 3.092

2.  Dosimetric coverage of the prostate, normal tissue sparing, and acute toxicity with high-dose-rate brachytherapy for large prostate volumes.

Authors:  George Yang; Tobin J Strom; Richard B Wilder; Kushagra Shrinath; Eric A Mellon; Daniel C Fernandez; Matthew C Biagioli
Journal:  Int Braz J Urol       Date:  2015 May-Jun       Impact factor: 1.541

3.  Prostate brachytherapy with iodine-125 seeds: analysis of a single institutional cohort.

Authors:  Elton Trigo Teixeira Leite; João Luis Fernandes da Silva; Eduardo Capelletti; Cecilia Maria Kalil Haddad; Gustavo Nader Marta
Journal:  Int Braz J Urol       Date:  2019 Mar-Apr       Impact factor: 1.541

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.